IR News & Topics

News

2026.04.22: Brincidofovir Shows Efficacy in Preclinical Study of EBV-Associated Gastric Carcinoma Poster Presentation Accepted at the ASCO Annual Meeting 2026
2026.04.21: Notice Regarding Notice of the Large Volume Exercise of the 66th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third-Party Allotment
2026.04.17: Notice regarding the Issuance of Stock Acquisition Rights (Stock Options) to the Company’s Directors
2026.04.17: Notice regarding the Issuance of Stock Acquisition Rights (Stock Options) to the Company’s Employees
2026.04.17: 訂正臨時報告書 (Japanese Only)
2026.04.06: Malignant Lymphoma: Journal Article on IV BCV Antitumor Effects, Mechanism of Action, and Sensitivity Biomarkers Published in BMC Medicine
2026.04.01: Notice Regarding the Monthly Exercise Status of the 58th and 66th Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued through Third-Party Allotment
2026.04.01: コーポレート・ガバナンスに関する報告書 2026/04/01 (Japanese only)
2026.03.31: 事業計画及び成長可能性に関する事項(Japanese only)
2026.03.30: CRADA with NIH/NINDS for Multiple Sclerosis Extended for Three Years — Following Progressive Multifocal Leukoencephalopathy, SymBio to Further Advance Development in the Neurodegenerative Disease Field —
2026.03.27: Notice Regarding the Acceleration of Exercise of the 66th Stock Acquisition Rights Issued through Third-Party Allotment
2026.03.27: 「動画で観るシンバイオ製薬」を更新しました。(Japanese only)
2026.03.27: 第21期定時株主総会の動画を掲載しました。(Japanese only)
2026.03.25: 臨時報告書(Japanese only)
2026.03.25: Notice of Shareholder Voting Results for the 21st Annual General Meeting of Shareholders
2026.03.24: Notice Concerning the Issuance of Stock Acquisition Rights to Directors
2026.03.24: Notice Concerning the Issuance of Stock Acquisition Rights to Employees
2026.03.24: Notice of Appointments to the Board Directors and Substitute Member of the Audit & Supervisory Committee, and Appointments of Corporate Officers
2026.03.24: 臨時報告書(Japanese only)
2026.03.24: 有価証券報告書－第21期(2025/01/01－2025/12/31)(Japanese only)
2026.03.23: Notice Regarding Conversion of the 7th Unsecured Convertible Bonds with Stock Acquisition Rights Issued through Third-Party Allotment, Early Redemption of the 1st Unsecured Straight Bonds, and Change in the Scheduled Timing of Expenditures of Funds Raised through the 65th to 67th Stock Acquisition Rights
2026.03.17: SymBio Achieves First Patient In (FPI) in Global Phase 3 Clinical Trial of IV BCV for Adenovirus Infection Following Hematopoietic Stem Cell Transplantation
2026.03.16: SymBio Secures Japan Patent for Use of IV BCV in Malignant Lymphoma — Accelerating Expansion into Oncology —
2026.03.02: Notice Regarding the Monthly Exercise Status of the 58th Stock Acquisition Rights Issued through Third-Party Allotment
2026.02.27: Notice of Convocation of the 21st Ordinary General Meeting of Shareholders
2026.02.27: Other Matters Subject to Measures for Electronic Provision for the 21st Annual Shareholders’ Meeting (Matters Omitted from the Delivered Documents)
2026.02.27: Information on Shareholders' Meeting: Updated the Page
2026.02.19: Notification of Amendment to the Articles of Incorporation
2026.02.19: Notice Regarding Nomination of Candidates for New Directors
2026.02.19: SymBio Receives Notice of Patent Grant in the U.S. for IV BCV Use Patent, Securing Patent Exclusivity Through 2044
2026.02.19: Completion, Monthly Exercise Status and Large Volume Exercise of the 65th Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued through Third-Party Allotment
2026.02.17: Announcement of FY2025 Grant Award for Research and Development of Orphan Drug for IV BCV for Adenovirus Infection Following Hematopoietic Stem Cell Transplantation
2026.02.17: 株主通信「SymBio VISION vol.28」(Japanese only)
2026.02.13: 2025年12月期決算説明会の動画を掲載しました。(Japanese only)
2026.02.10: 決算説明会資料（2025年12月期）(Japanese only)
2026.02.09: IV Brincidofovir Phase 2 Clinical Trial Results in CMV Infection Following Hematopoietic Stem Cell Transplantation Presented Orally at the Tandem Meetings
2026.02.05: Summary of Financial Statements for the Fiscal Year Ended December 31, 2025 [Japanese GAAP] (Consolidated)
2026.02.02: Notice Regarding the Monthly Exercise Status of the 58th and 65th Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued through Third-Party Allotment
2026.02.02: SymBio Announces Cooperative Agreement with the NIH to Test IV Brincidofovir for Treating Progressive Multifocal Leukoencephalopathy
2026.01.29: A New Approach to Multiple Sclerosis Treatment Using IV BCV Research Results from a Collaborative Study with the U.S. NIH Published in the Journal of Clinical Investigation
2026.01.16: Notice Regarding Notice of the Large Volume Exercise of the 65th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third-Party Allotment
2026.01.05: Notice Regarding the Monthly Exercise Status of the 58th and 65th Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued through Third-Party Allotment
2026.01.05: Notice of Appointment of Corporate Officer Appointment of Minori Rosales as Corporate Officer and Head of Japan Development Division Strengthening the Global Expansion of IV BCV

2025.12.26: Notice Regarding Notice of the Large Volume Exercise of the 65th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third-Party Allotment
2025.12.25: SymBio Announces Exclusive Global License Agreement with Tufts University for Treatment of Alzheimer’s Disease with IV BCV
2025.12.24: SymBio Announces Exclusive Global License Agreement with Penn State Research Foundation for Treatment of Polyomavirus Infections with IV BCV
2025.12.22: SymBio Receives Notice of Allowance in the U.S. for IV BCV Use Patent, Securing Exclusivity Through 2044
2025.12.01: Notice Regarding the Monthly Exercise Status of the 58th and 65th Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued through Third-Party Allotment
2025.12.01: Notice of Appointment of Corporate Officers
2025.11.27: SymBio Presents Research Findings on Brincidofovir for the Treatment of Malignant Brain Tumors (Glioblastoma) at the Society for Neuro-Oncology (SNO) Annual Meeting
2025.11.20: Prioritizing and Focusing Resources on the Global Phase 3 Trial of IV Brincidofovir for Adenovirus Infection Post-HSCT - Portfolio Reprioritization
2025.11.17: SymBio Obtains Clinical Trial Authorization in the United Kingdom for the Global Phase 3 Clinical Study of Intravenous Brincidofovir in Adenovirus Infection Following Hematopoietic Stem Cell Transplantation
2025.11.04: Notice Regarding the Monthly Exercise Status of the 58th and 65th Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued through Third-Party Allotment
2025.10.30: Summary of Consolidated Financial Statements for the First Nine Months of the Fiscal Year Ending December 31, 2025 [Japanese GAAP]
2025.10.28: SymBio Receives MHRA Approval of its Pediatric Investigation Plan, a Requirement for Initiating the Global Phase 3 Study Evaluating IV Brincidofovir for the Treatment of Adenovirus Infection Post-HSCT in the United Kingdom
2025.10.27: SymBio Presents Positive Efficacy Data for Brincidofovir in Head and Neck Cancer at ESMO 2025 (Berlin, Germany)
2025.10.24: Notice Regarding Notice of the Large Volume Exercise of the 65th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third-Party Allotment
2025.10.20: Patent Obtained for a Groundbreaking Immunoassay with Ultra-High Sensitivity (detection at one part in a trillion)
2025.10.15: SymBio Receives Regulatory Approval in Spain to Proceed with its Phase 3 Global Study Evaluating IV Brincidofovir for the Treatment of Adenovirus Infection After HSCT
2025.10.07: SymBio Submits Clinical Trial Application to the UK’s MHRA for the Phase 3 Global Study Evaluating IV Brincidofovir for the Treatment of Adenovirus Infection After HSCT
2025.10.06: SymBio Initiates Global Phase 3 Trial of IV Brincidofovir for the Treatment of Adenovirus Infection Post-HSCT, Following Regulatory Approval in Three Major European Countries
2025.10.01: Notice Regarding the Monthly Exercise Status of the 58th and 65th Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued through Third-Party Allotment
2025.10.01: Notice Regarding Notice of the Large Volume Exercise of the 65th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third-Party Allotment
2025.09.30: IV Brincidofovir for Treatment of Adenovirus Infection after HSCT Receives Orphan Drug Designation from Japan’s Ministry of Health, Labour and Welfare
2025.09.29: SymBio Presents Preclinical Results on the Use of Brincidofovir in Malignant Brain Tumors at the Annual Meeting of the Japanese Cancer Association
2025.09.17: SymBio Secures EMA Approval of the Pediatric Investigation Plan (PIP) for IV Brincidofovir, a Requirement for Initiating the Global Phase 3 Study for Adenovirus Infection following HSCT
2025.09.01: Notice Regarding the Monthly Exercise Status of the 58th and 65th Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued through Third-Party Allotment
2025.08.26: Notice Regarding the Completion of Payment for the 1st Unsecured Straight Bonds
2025.08.18: Analyst Report[Full report] (Shared Research)
2025.08.12: 2025年12月期中間決算説明会の動画を掲載しました。(Japanese only)
2025.08.12: Notice Regarding the Completion of Payment for the Issue Price of the Issuance of the 65th to 67th Stock Acquisition Rights (with Exercise Price Adjustment Clauses) through Third-Party Allotment
2025.08.12: Notice Regarding Adjustment of Conversion Price
2025.08.12: Notice Regarding Adjustment of Exercise Price
2025.08.12: SymBio Announces Abstract on Brincidofovir for the Treatment of Malignant Brain Tumors (Glioblastoma) Accepted for Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting to be Held in November 2025
2025.08.05: 中間決算説明会資料（2025年12月期）(Japanese only)
2025.08.04: 半期報告書－第21期(2025/01/01－2025/12/31) (Japanese only)
2025.08.04: Notice Regarding Publication of a Review Article on Evaluation of Brincidofovir as Potential Treatment for Mpox by Licensor Emergent BioSolutions
2025.08.01: Notice of Appointment of Corporate Officer
2025.07.31: Summary of Consolidated Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2025 [Japanese GAAP]
2025.07.28: SymBio to Present Preclinical Data on Brincidofovir in Head and Neck Cancer at ESMO 2025 Congress
2025.07.22: Notice Concerning the Treatment of the 58th Stock Acquisition Rights in Light of the Issuance of the 65th to 67th Stock Acquisition Rights
2025.07.22: Notice Regarding the Issuance of the 65th to 67th Stock Acquisition Rights (with Exercise Price Adjustment Clauses) through Third-Party Allotment and the Execution of a Purchase Agreement (Commit Issue) for the 1st Unsecured Straight Bonds and Stock Acquisition Rights
2025.06.30: SymBio Submits Clinical Trial Application for a Phase 3 Global Study Evaluating IV Brincidofovir for the Treatment of Adenovirus Infection after HSCT
2025.06.18: Comprehensive Review of the Development of Brincidofovir for Diverse Indications Published by Wiley
2025.06.10: Revision to Earnings Forecast for FY 2025
2025.06.10: SymBio Announces Enrollment of the First Patient in International Phase Ib/II Clinical Trial of IV Brincidofovir for Malignant Lymphoma
2025.06.03: Key person interview: Updated the Page
2025.05.16: 株主通信「SymBio VISION vol.27」(Japanese only)
2025.05.12: SymBio Confirms Brincidofovir (BCV) Efficacy Against Malignant Brain Tumors and Identification of Biomarker Genes (Predictive Factors of Efficacy)
2025.05.08: Summary of Consolidated Financial Statements for the First Three Months of Fiscal Year Ending December 31, 2025 [Japanese GAAP]
2025.04.21: Notice regarding the Issuance of Stock Acquisition Rights(Stock Options) to the Company’s Directors
2025.04.21: Notice regarding the Issuance of Stock Acquisition Rights (Stock Options) to the Company’s Employees
2025.04.21: 訂正臨時報告書 (Japanese only)
2025.04.18: 訂正臨時報告書 (Japanese only)
2025.04.11: Notice Regarding the Completion of Payment for the Issuance of the 7th Unsecured Convertible Bonds with Stock Acquisition Rights through Third-Party Allotment
2025.04.03: コーポレート・ガバナンスに関する報告書 2025/04/03 (Japanese only)
2025.03.31: 事業計画及び成長可能性に関する事項(Japanese only)
2025.03.28: 「動画で観るシンバイオ製薬」を更新しました。(Japanese only)
2025.03.28: 第20期定時株主総会の動画を掲載しました。(Japanese only)
2025.03.26: Notice of Shareholder Voting Results for the 20th Annual General Meeting of Shareholders
2025.03.25: Notice Regarding Adjustment of Exercise Price
2025.03.25: Notice Concerning the Issuance of Stock Acquisition Rights to Directors
2025.03.25: Notice Concerning the Issuance of Stock Acquisition Rights to Employees
2025.03.25: Notice of Appointments to the Board Directors and Substitute Member of the Audit & Supervisory Committee, and Appointments of Corporate Officers
2025.03.25: Notice Regarding the Issuance of the 7th Unsecured Convertible Bonds with Stock Acquisition Rights through Third-Party Allotment Based on the Agreement to Establish a Bond Issuance Program with Stock Acquisition Rights
2025.03.17: Notice of Appointment of Senior Vice President, Head of R&D of SymBio Pharma USA, Inc.
2025.03.15: Partial Revision of the Press Release Entitled, “Announcing the Convocation of the Annual Meeting of Shareholders for the Year Ended December 31, 2024”
2025.03.15: Notice of Convocation of the 20th Ordinary General Meeting of Shareholders
2025.03.03: Analyst Report[Full report] (Shared Research)
2025.02.27: Notice of Convocation of the 20th Ordinary General Meeting of Shareholders
2025.02.27: Information on Shareholders' Meeting: Updated the Page
2025.02.26: 2024年12月期決算説明会の動画を掲載しました。(Japanese only)
2025.02.20: Notice Regarding the Cancellation of the Issuance of the 6th Unsecured Convertible Bonds with Stock Acquisition Rights and Change in the Use of Net Proceeds
2025.02.13: 決算説明会資料（2024年12月期）(Japanese only)
2025.02.06: Notice Regarding Change in Allotment Resolution Dates for the 6th and 7th Unsecured Convertible Bonds with Stock Acquisition Rights
2025.02.06: Summary of Financial Statements for the Fiscal Year Ended December 31, 2024 [Japanese GAAP]（Consolidated）
2025.02.06: SymBio Initiates Phase 1b/2 Clinical Trial of IV Brincidofovir in Patients with Lymphoma in Singapore
2025.02.05: Notice Regarding the Completion of Payment for the Issuance of the 5th Unsecured Convertible Bonds with Stock Acquisition Rights through Third-Party Allotment
2025.01.20: Notice Regarding Adjustment of Exercise Price
2025.01.20: Notice Regarding the Issuance of the 5th Unsecured Convertible Bonds with Stock Acquisition Rights through Third-Party Allotment Based on the Agreement to Establish a Bond Issuance Program with Stock Acquisition Rights
2025.01.10: Notice Regarding the Completion of Payment for the Issuance of the 4th Unsecured Convertible Bonds with Stock Acquisition Rights through Third-Party Allotment

2024.12.27

Notice of Personnel Changes at SymBio Pharma USA, Inc.

2024.12.26

株主通信「SymBio VISION vol.26」(Japanese only)

2024.12.25

Notice Regarding the Conclusion of Agreement to Establish a Bond Issuance Program with Stock Acquisition Rights and the Issuance of the 4th Unsecured Convertible Bonds with Stock Acquisition Rights through Third-Party Allotment

2024.12.25

Notice Regarding Adjustment of Exercise Price

2024.12.13

Research Results on the Antitumor Effects of Intravenous Brincidofovir and its Potential Use as a Therapy in Combination with Immune Checkpoint Inhibitors to be Presented at the 66th Annual Meeting of the American Society of Hematology

2024.11.20

SymBio Presents Research Results Showing Potential Use of Intravenous Brincidofovir in Combination with Immune Checkpoint Inhibitors as a Therapy for Malignant Lymphoma at the 66th the American Society of Hematology Annual Meeting

2024.11.05

Notice of Appointment of Corporate Vice President and Global CMO

2024.10.31

Summary of Consolidated Financial Statements for the First Nine Months of Fiscal Year Ending December 31, 2024 [Japanese GAAP]

2024.10.23

SymBio presents data from Phase IIa clinical trial showing clinical efficacy of IV BCV in treating symptoms of adenovirus infection

2024.09.30

SymBio Reaches Settlement Agreement in Patent Infringement Litigation Related to TREAKISYM

2024.09.30

Analyst Report[Follow-up Report] (Fair Research)

2024.09.18

Key person interview: Updated the Page

2024.08.19

SymBio Initiates Phase 1b Clinical Trial of IV Brincidofovir in Patients with Lymphoma as a First in Human Study for Oncology

2024.08.14

中間決算説明会スクリプト（2024年12月期）(Japanese only)

2024.08.13

Article on 2024 1H Earnings Call Featured in Nikkei Biotech Online (Japanese only)

Source: Nikkei Biotech ONLINE, 2024.08.07

Although Nikkei BP grants permission to use the articles, the content of the articles does not constitute a recommendation to purchase/invest in a specific company/organization or product/service.
Unauthorized reproduction, duplication, or electronic storage of the articles/photos/charts, etc. is prohibited.

2024.08.08